FIELD: medicine.
SUBSTANCE: invention relates to antibody-drug conjugates wherein the antibodies specifically bind to the transferrin receptor TFR and the drugs are preferably selected from cytotoxic agents. The invention relates to antibody-drug conjugates, where the antibodies specifically bind to the transferrin receptor TFR and the drug is monomethylauristatin E.
EFFECT: such antibody-drug conjugates can be used in particular in the treatment of proliferative diseases, including cancer diseases such as lymphomas or leukemias.
10 cl, 10 dwg, 8 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
